Yunge Zhao1, Jacob R Gillen1, Akshaya K Meher1, Jordan A Burns1, Irving L Kron1, Christine L Lau2. 1. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Va. 2. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Va. Electronic address: cll2y@virginia.edu.
Abstract
OBJECTIVE: B lymphocytes are generally considered to be activators of the immune response; however, recent findings have shown that a subtype of B lymphocytes, regulatory B lymphocytes, play a role in attenuating the immune response. Bronchiolitis obliterans remains the major limitation to modern-day lung transplantation. The role of regulatory B lymphocytes in bronchiolitis obliterans has not been elucidated. We hypothesized that regulatory B lymphocytes play a role in the attenuation of bronchiolitis obliterans. METHODS: We performed a standard heterotopic tracheal transplant model. Tracheas from Balb/c mice were transplanted into C57BL/6 recipients. Rapamycin treatment and dimethyl sulfoxide control groups were each treated for the first 14 days after the transplant. Tracheas were collected on days 7, 14, and 28 post-transplantation. Luminal obliteration was evaluated by hematoxylin-eosin staining and Picrosirius red staining. Immune cell infiltration and characteristics, and secretion of interleukin-10 and transforming growth factor-β1 were accessed by immunohistochemistry. Cytokines and transforming growth factor-β1 were measured using the Luminex assay (Bio-Rad, Hercules, Calif). RESULTS: The results revealed that intraperitoneal injection of rapamycin for 14 days after tracheal transplantation significantly reduced luminal obliteration on day 28 when compared with the dimethyl sulfoxide control group (97.78% ± 3.63% vs 3.02% ± 2.14%, P < .001). Rapamycin treatment markedly induced regulatory B lymphocytes (B220(+)IgM(+)IgG(-)IL-10(+)TGF-β1(+)) cells when compared with dimethyl sulfoxide controls. Rapamycin treatment inhibited interleukin-1β, 6, 13, and 17 on days 7 and 14. Rapamycin also greatly increased interleukin-10 and transforming growth factor-β1 production in B cells and regulatory T lymphocytes infiltration on day 28. CONCLUSIONS: Mammalian target of rapamycin inhibition decreases the development of bronchiolitis obliterans via inhibition of proinflammatory cytokines and increasing regulatory B lymphocytes cell infiltration, which subsequently produces anti-inflammatory cytokines and upregulates regulatory T lymphocyte cells. Published by Elsevier Inc.
OBJECTIVE: B lymphocytes are generally considered to be activators of the immune response; however, recent findings have shown that a subtype of B lymphocytes, regulatory B lymphocytes, play a role in attenuating the immune response. Bronchiolitis obliterans remains the major limitation to modern-day lung transplantation. The role of regulatory B lymphocytes in bronchiolitis obliterans has not been elucidated. We hypothesized that regulatory B lymphocytes play a role in the attenuation of bronchiolitis obliterans. METHODS: We performed a standard heterotopic tracheal transplant model. Tracheas from Balb/c mice were transplanted into C57BL/6 recipients. Rapamycin treatment and dimethyl sulfoxide control groups were each treated for the first 14 days after the transplant. Tracheas were collected on days 7, 14, and 28 post-transplantation. Luminal obliteration was evaluated by hematoxylin-eosin staining and Picrosirius red staining. Immune cell infiltration and characteristics, and secretion of interleukin-10 and transforming growth factor-β1 were accessed by immunohistochemistry. Cytokines and transforming growth factor-β1 were measured using the Luminex assay (Bio-Rad, Hercules, Calif). RESULTS: The results revealed that intraperitoneal injection of rapamycin for 14 days after tracheal transplantation significantly reduced luminal obliteration on day 28 when compared with the dimethyl sulfoxide control group (97.78% ± 3.63% vs 3.02% ± 2.14%, P < .001). Rapamycin treatment markedly induced regulatory B lymphocytes (B220(+)IgM(+)IgG(-)IL-10(+)TGF-β1(+)) cells when compared with dimethyl sulfoxide controls. Rapamycin treatment inhibited interleukin-1β, 6, 13, and 17 on days 7 and 14. Rapamycin also greatly increased interleukin-10 and transforming growth factor-β1 production in B cells and regulatory T lymphocytes infiltration on day 28. CONCLUSIONS:Mammalian target of rapamycin inhibition decreases the development of bronchiolitis obliterans via inhibition of proinflammatory cytokines and increasing regulatory B lymphocytes cell infiltration, which subsequently produces anti-inflammatory cytokines and upregulates regulatory T lymphocyte cells. Published by Elsevier Inc.
Entities:
Keywords:
FoxP3β regulatory T cells; bronchiolitis obliterans; mouse heterotopic tracheal transplant; rapamycin; regulatory B lymphocytes
Authors: Koichi Yanaba; Jean-David Bouaziz; Karen M Haas; Jonathan C Poe; Manabu Fujimoto; Thomas F Tedder Journal: Immunity Date: 2008-05 Impact factor: 31.745
Authors: M Okazaki; A S Krupnick; C G Kornfeld; J M Lai; J H Ritter; S B Richardson; H J Huang; N A Das; G A Patterson; A E Gelman; D Kreisel Journal: Am J Transplant Date: 2007-06 Impact factor: 8.086
Authors: Takashi K Kishimoto; Joseph D Ferrari; Robert A LaMothe; Pallavi N Kolte; Aaron P Griset; Conlin O'Neil; Victor Chan; Erica Browning; Aditi Chalishazar; William Kuhlman; Fen-Ni Fu; Nelly Viseux; David H Altreuter; Lloyd Johnston; Roberto A Maldonado Journal: Nat Nanotechnol Date: 2016-08-01 Impact factor: 39.213
Authors: Daniel Fantus; Helong Dai; Yoshihiro Ono; Alicia Watson; Shinichiro Yokota; Kanishka Mohib; Osamu Yoshida; Mark A Ross; Simon C Watkins; Bala Ramaswami; Anna Valusjkikh; David M Rothstein; Angus W Thomson Journal: Transplantation Date: 2017-12 Impact factor: 4.939
Authors: Marniker Wijesinha; Jon Mark Hirshon; Michael Terrin; Laurence Magder; Clayton Brown; Kristen Stafford; Aldo Iacono Journal: JAMA Netw Open Date: 2019-08-02